ImmunityBio
ImmunityBio50
About
What does ImmunityBio do?
ImmunityBio is a biotechnology company developing immunotherapies to treat cancer and infectious diseases by activating the patient's innate and adaptive immune systems. Their approach aims to deliver durable responses by stimulating various immune cells and building immunological memory. The company's investigational products, including ANKTIVA®, are designed to reprogram the immune system to conquer difficult diseases.
What is ImmunityBio's revenue?
StartupHub estimates ImmunityBio's annual revenue at $69.4M (range $38.3M to $232.0M, 68% confidence), based on comparable companies in the sector.
What is ImmunityBio's valuation?
StartupHub estimates ImmunityBio's effective valuation at $1.6B (range $929.4M to $3.9B, 55% confidence), based on comparable companies in the sector.
How much funding has ImmunityBio raised?
ImmunityBio has raised a total of $75M in funding. The most recent round on record is Funding Round.
Where is ImmunityBio headquartered?
ImmunityBio is headquartered in Culver City, California, USA.
When was ImmunityBio founded?
ImmunityBio was founded in 2014.
What industry does ImmunityBio operate in?
ImmunityBio operates in Biotechnology, Pharmaceuticals, Healthcare, Immunotherapy, Biotech, HealthTech.
How many employees does ImmunityBio have?
ImmunityBio has approximately 620 people on record.
No comments yet. Be the first to share your take.